Ingenol mebutate gel 0.015% and 0.05%: In actinic keratosis

Drugs

Volumn 72, Issue 18, 2012, Pages 2397-2405

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Actinic keratosis; Adis Drug Profiles; Ingenol mebutate

Indexed keywords

DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE;

ABLATION THERAPY; ACTINIC KERATOSIS; ARTICLE; AUSTRALIA; BRAZIL; CRYOTHERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FACE; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTICENTER STUDY (TOPIC); PHOTODYNAMIC THERAPY; PLANT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAP FLOW; SCALP; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; ULTRAVIOLET RADIATION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

DITERPENES; GELS; HUMANS; KERATOSIS, ACTINIC; PROTEIN KINASE C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EUPHORBIA PEPLUS;

EID: 84871217196     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11470090-000000000-00000     Document Type: Article

References (27)

1. de Berker D, McGregor JM, Hughes BR, et al. Guidelines for the management of actinic keratoses. Br J Dermatol 2007 Feb; 156 (2); 222-30
2. Del Rosso JQ. Current regimens and guideline implications for the treatment of actinic keratosis; proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference. Cutis 2011 Jul; 88 Suppl. 1; 1-8
3. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009 Jun; 60 (6); 934-43
4. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses; rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 2012 Mar; 66 (3); 486-93
5. Barnaby JWJ, Styles AR, Cockerell CJ. Actinic keratoses; differential diagnosis and treatment. Drugs Aging 1997 Sep; 11 (3); 186-205
6. Ramsay JR, Suhrbier A, Aylward JH, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol 2011 Mar; 164 (3); 633-6
7. Rizk AM, Hammouda FM, El-Missiry MM, et al. Biologically active diterpene esters from Euphorbia peplus. Phytochem 1985; 24 (7); 1605-6
8. LEO Pharma, Inc. Picato® (ingenol mebutate) gel, 0.015% and 0.05% for topical use; US prescribing information. online. Available from URL; :http://www.leo-pharma.us/Files/Billeder/LEO-local-images/LEO-Pharma.US/ Releases/Picato%20PI.pdf. Accessed 2012 Jun 28.
9. European Medicines Agency. Picato (ingenol mebutate) gel; EU summary of product characteristics. online. Available from URL; :http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002275/WC500135327. pdf. Accessed 2012 Dec 3.
10. Stahlhut M, Chahal H, Lord J, et al. Ingenol mebutate initiates multiple specific cell death pathways in human cancer cells. abstract no. 5517. J Am Acad Dermatol 2012 Apr; 66 (4 Suppl. 1); AB152
11. Zibert JR, Eriksson AH, Grue-Sørensen G, et al. Ingenol mebutate penetrates reconstructed human skin in a gradient-dependent manner and clears subclinical skin cancer. abstract no. 5501. J Am Acad Dermatol Apr; 66 (4 Suppl. 1); AB152
12. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006 Dec 1; 177 (11); 8123-32
13. Ogbourne S, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate; plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004 Apr 15; 64 (8); 2833-9
14. Hampson P, Kavanagh D, Smith E, et al. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner. Cancer Immunol Immunother 2012 Aug; 57 (8); 1241-51
15. Kedei N, Lundberg DJ, Toth A, et al. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 2004 May 1; 64 (9); 3243-55
16. Ersvaer E, Kittang AO, Hampson P, et al. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer; a balance between efficacy and toxicity. Toxins 2010 Jan; 2 (1); 174-94
17. Li L, Shukla S, Lee A, et al. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res 2010 Jun 1; 70 (11); 4509-19
18. Cozzi S-J, Ogbourne SM, James C, et al. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol 2012 Apr; 132 (4); 1263-71
19. Peplin. A study to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) gel, 0.05%, when applied in a maximal use setting to the dorsal aspect of the forearm in patients with actinic keratosis. ClinicalTrials.gov identifier NCT00852137. US National Institutes of Health, ClinicalTrials.gov. online. Available from URL; :http://www.clinicaltrials/gov. Accessed 2012 Jun 28.
20. Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis; results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol 2009 Feb; 50 (1); 16-22
21. Spencer J. Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01%, and 0.015% when used to treat actinic keratoses on the head. abstract no. P2913. J Am Acad Dermatol 2010 Mar; 62 (3 Suppl. 1); AB105
22. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012 Mar 15; 366 (11); 1010-9
23. Berman B, Marmur E, Larsson T, et al. Three-day topical treatment with ingenol mebutate gel 0.015% for actinic keratoses on the face and scalp; analysis of data pooled from two trials. poster no. 5623. 70th Annual Meeting of the American Academy of Dermatology; 2012 Mar 16-20; San Diego (CA
24. Anderson LL, Schmieder GJ, Xu Z, et al. Two-day topical treatment with ingenol mebutate gel 0.05% for actinic keratoses on the trunk and extremities; analysis of data pooled from two trials. poster no. 5640. 70th Annual Meeting of the American Academy of Dermatology; 2012 Mar 16-20; San Diego (CA)
25. Stein Gold L, Melgaard A, Larsson T. Long-term follow-up studies of ingenol mebutate gel for the treatment of actinic keratosis. abstract no. 5620. J Am Acad Dermatol 2012 Apr; 66 (4 Suppl. 1); AB154. Plus poster presented at the 70th Annual Meeting of the American Academy of Dermatology; 2012 Mar 16-20; San Diego (CA)
26. Peplin. A multi-center study to evaluate the safety and efficacy of PEP005 (ingenol mebutate) gel, when used to treat actinic keratoses on non-head locations (trunk and extremities). ClinicalTrials.gov identifier NCT00917306. US National Institutes of Health, ClinicalTrials.gov. online. Available from URL; :http://www.clinicaltrials/gov. Accessed 2012 Jul 16.
27. Lebwohl M, Swanson N, Kobayashi K, et al. Local skin responses associated with ingenol mebutate gel for the treatment of actinic keratosis; two analyses of pooled data. poster no. 4997. 70th Annual Meeting of the American Academy of Dermatology; 2012 Mar 16-20; San Diego (CA